within Pharmacolibrary.Drugs.ATC.L;

model L04AA22
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,
    adminCount     = 1,
    Vd             = 0.004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Abetimus is a synthetic double-stranded oligonucleotide that acts as an immunosuppressive agent by inhibiting the production of anti-double stranded DNA antibodies. It was developed for the treatment of systemic lupus erythematosus (SLE) but was never approved, and its development has been discontinued.</p><h4>Pharmacokinetics</h4><p>Estimated PK parameters based on pharmacological class and physicochemical properties, as no published clinical pharmacokinetic data are available for abetimus in humans.</p><h4>References</h4><ol><li><p>Linnik, MD, et al., &amp; Crowther, MA (2008). Pharmacokinetics of high-dose abetimus sodium in normal subjects with specific assessment of effect on coagulation. <i>Journal of clinical pharmacology</i> 48(8) 909â€“918. DOI:<a href=&quot;https://doi.org/10.1177/0091270008319465&quot;>10.1177/0091270008319465</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18511650/&quot;>https://pubmed.ncbi.nlm.nih.gov/18511650</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AA22;
